Wednesday, 14 Nov 2018

You are here

Osteoarthritis and the Risk of Mortality

Osteoarthritis (OA) affects 27 million Americans but its affect on mortality is uncertain. A recent study shows that while self-reported OA does not increase mortality, radiographic OA of the knee (RKOA) is associated with higher mortality related to CVD, diabetes and renal disease.

An analysis of adults in the 1988–94 and 1999–2010 National Health and Nutrition Examination Survey (NHANES) data looked at age related, self-reported and radiographic knee OA (RKOA) defined as Kellgren–Lawrence score ≥2. 

Among a sample of 51938 participants, 2589 of them had knee X-rays, with a prevalence of 6.6%. By contrast self-reported OA was seen in 40.6%. The latter was not associated with mortality.

RKOA was associated with an increased risk of mortality from cardiovascular diseases (CVD) {HR 1.43 [95% confidence interval (CI): 1.32, 1.64]}, diabetes [HR 2.04 (1.87, 2.23)] and renal diseases [HR 1.14 (1.04, 1.25)].  Conversely RKOA was associated with a reduced risk of cancer mortality [HR 0.88 (0.80, 0.96)].

Those diagnosed with early RKOA onset (before age 40) had a higher risk of mortality from all causes [HR 1.53 (1.43, 1.65)] and from diabetes [HR 7.18 (5.45, 9.45)].

Obese participants with RKOA were at increased risk of mortality from CVD [HR 1.89 (1.56, 2.29)] and from diabetes [HR: 3.42 (3.01, 3.88)].

 

Disclosures: 
The author has no conflicts of interest to disclose related to this subject

Add new comment

More Like This

Pre-Diabetes Associated Risk for Arthritis, Obesity and Physical Inactivity

The current MMWR reports that arthritis is seen in nearly one-third of adults with prediabetes and that more than half of such patients are obese and not engaged in regular physical activity.

Doctor-diagnosed arthritis affects 54.4 million in the U.S. and the CDC expects this to rise to 78.4 million by 2040.

Controversial New Super Opioid Approved by FDA

Amidst a new DEA report demonstrating a record number of opioid overdose deaths (n-72,000 or ~ 200 deaths per day), the FDA has approved a newer and far more potent opioid than those that are currently being abused at alarming rates. The new agent is named Dsuvia.

Late Breaker: Can Tanezumab Be Revived for OA?

The monoclonal antibody tanezumab, which blocks nerve growth factor, showed significant benefits in pain and function among patients with osteoarthritis (OA) of the knee or hip, and rates of severe adverse joint events such as rapidly progressive OA that had plagued earlier studies were low, a researcher reported at the annual meeting of the American College of Rheumatology in Chicago last week.

Vitamin D Fails to Improve Bone Health

The current edition of Lancet Diabetes & Endocrinology suggests that neither vitamin D supplementation, nor dose, will improve bone density or prevent fractures in adults. (Citation source: https://buff.ly/2O9tqxI)

Zolendronic Acid Benefits Elder Women with Osteopenia

The NEJM reports that zolendronic acid was shown to significantly lower the risk of nonvertebral or vertebral fragility fractures in older women with osteopenia.